EUVIMEDEUVIMED entdecken
Crossref

Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients—From discovery to treatment

Zvi Laron, Rivka Kauli

Growth Hormone & IGF Research · 2016-06 · 28 · 53-56

DOI: 10.1016/j.ghir.2015.08.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Growth Hormone & IGF Research, 2016-06. Verfasst von Zvi Laron und 1 weiteren Autor:innen. Beteiligte Einrichtung: Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel. Electronic address: Laronz@clalit.org.il. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical and laboratory investigations of dwarfed children newly Jewish immigrants from Yemen and Middle East and who resembled patients with isolated growth hormone deficiency were started by our group in 1958. In 1963 when we found that they have high serum levels of hGH, we knew that we had discovered a new disease of primary GH insensitivity. It was subsequently coined Laron Syndrome (LS, OMIM #262500). The etiopathogenesis was disclosed by 2 liver biopsies demonstrating a defect in the GH receptor. Subsequent investigations demonstrated deletions or mutations in the GHR gene. The defect lead to an inability of IGF-I generation, resulting in severe dwarfism, obesity, and other morphologic and biochemical pathologies due to IGF-I deficiency. With the biosynthesis of IGF-I in 1986, therapeutic trials started. Following closely our cohort of 69 patients with LS enabled us to study its features in untreated and IGF-I treated patients. This syndrome proved to be a unique model to investigate the effects of IGF-I dissociated from GH stimulation. In recent studies we found that homozygous patients for the GHR mutations are protected lifelong from developing malignancies, opening new directions of research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdolescentAdultChildChild, PreschoolCohort StudiesFemaleFollow-Up StudiesHumansInfantInfant, NewbornInsulin-Like Growth Factor IIsraelJewsLaron SyndromeMaleMiddle AgedMiddle EastNeoplasmsProtective FactorsReceptors, Somatotropin

Stichwörter der Autor:innen

DwarfismGH insensitivityIGF-IIGF-I treatmentLaron syndromeObesity

Substanzen

Receptors, SomatotropinInsulin-Like Growth Factor I

Autor:innen und Institutionen

  • Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel. Electronic address: Laronz@clalit.org.il.
  • Schneider Children's Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel.

Zitieren

APA

Laron, Z., & Kauli, R. (2016). Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients—From discovery to treatment. Growth Hormone & IGF Research, 28, 53-56. https://doi.org/10.1016/j.ghir.2015.08.004

Vancouver

Laron Z, Kauli R. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients—From discovery to treatment. Growth Hormone & IGF Research. 2016;28:53-56. doi:10.1016/j.ghir.2015.08.004

BibTeX
@article{Laron2016,
  author = {Laron, Zvi and Kauli, Rivka},
  title = {Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients—From discovery to treatment},
  journal = {Growth Hormone & IGF Research},
  year = {2016},
  volume = {28},
  pages = {53--56},
  doi = {10.1016/j.ghir.2015.08.004}
}
Kostenlos starten →